Pfizer Inc. (PFE) News and Global Healthcare & Biopharma Updates
Pfizer Inc., headquartered in New York City, is one of the world’s largest biopharmaceutical companies. Its portfolio spans vaccines, oncology, cardiology, and rare diseases. Known globally for developing the first widely distributed COVID-19 vaccine with BioNTech, Pfizer continues to advance innovation in immunology, mRNA technology, and breakthrough medicines to improve global health outcomes.
24.14
0.5850
2.37 %
At close
06/24
USD
Daily range
23.93
25.11
25.11
Weekly range
24.69
25.34
25.34
Sigvotatug vedotin trial failure sends Pfizer stock down nearly 3%
Pfizer (PFE) stock is trading at $23.98, closing down 2.99% for the day. The share price ended the session below its key moving averages, reflecting ongoing downside ...
-3.08% for Pfizer stock as CFO Dave Denton steps down
Pfizer Inc. (PFE) stock is trading at $25.17, down 3.08% on the day. The price remains below its key moving averages, reflecting continued pressure in the current ...
Pfizer stock climbs as dividend yield attracts income investors
Pfizer Inc. (PFE) stock is trading at $26.26, up 2.56% on the day. The stock sits above its main short-term and long-term moving averages, reflecting positive momentum ...
Pfizer stock edges higher to $25.66 as Pfizer presents blood disorder data at EHA2026
Pfizer is presenting more than 20 abstracts at EHA2026 in Stockholm this week.The company is focusing on blood cancers, sickle cell disease, and hemophilia. Pfizer states it is committed to ...
Pfizer advances obesity treatment pipeline as stock trades near weekly highs
Pfizer announced new Phase 2b data for its investigational GLP‑1 RA peptide, showing robust efficacy and favourable gastrointestinal tolerability with weekly and monthly dosing.The company said ...
Pfizer stock sees mild rebound above $25.98 but upside momentum capped near resistance
Pfizer stated that not all migraine attacks are random and that hormonal shifts during the menstrual cycle can trigger longer, more severe symptoms.The company said that understanding the science ...
Pfizer stock edges higher 1.32% as company announces new Phase 2b obesity data at ADA event
Pfizer announced that new Phase 2b data from its obesity pipeline will be presented at a late-breaking expert symposium during the #ADASciSessions this weekend.Pfizer stated that it is working to ...
Selling pressure pushes Pfizer stock lower in today's trading
Pfizer Inc. (PFE) is trading at $25.65, down 2.12% on the day. The stock sits just below its 20-day moving average at $25.98 and well under the 50-day at $26.73, but remains slightly above the ...
-3.15% for Pfizer stock as new share registration weighs on outlook
Pfizer Inc. (PFE) is trading at $25.65, marking a daily decline of 3.15%. The asset is currently positioned below its key moving averages, which reflects sustained ...
Pfizer stock slides 2.52% as company highlights CDK research progress in metastatic breast cancer
Pfizer scientists have made progress toward potential new therapies for certain forms of metastatic breast cancer.Pfizer is studying CDKs, enzymes that drive cell cycle progression, as part of ...
What is behind Pfizer stock's recent drop in value today
Pfizer Inc. (PFE) is trading at $26.88, down 3.41% on the day, and remains below its 20-day and 50-day moving averages, but above its 200-day moving average. This setup reflects ongoing short- to ...
ATTR-CM research drive sees Pfizer stock down 1.07% amid overbought technical readings
Pfizer is advancing research into ATTR-CM, a rare and serious heart condition that is underrecognized and underdiagnosed.The company says early, accurate diagnosis is important for patients with ...
+1.26% for Pfizer stock as buyers keep price above key moving averages
Pfizer is sharing data from its lung cancer pipeline at ELCC2026. The company says it is working to set new standards for impact in lung cancer care.Pfizer describes its pipeline as innovative and ...
Pfizer unveils new lung cancer molecule data at ELCC2026 to drive advances in care
Pfizer has presented new data from its innovative lung cancer pipeline featuring novel and differentiated molecules at ELCC2026. The company aims to set new standards for meaningful impact in ...
What triggered Pfizer shares' latest price pullback
Pfizer Inc. (PFE) is trading at $26.86, just below the SMA-20 ($27.01), above the SMA-50 ($26.59), and higher than the SMA-200 ($25.28). This positioning suggests some short-term resistance but an ...
+3.04% for Pfizer stock — Strong R&D focus and positive drug news lift shares
Pfizer Inc. (PFE) is trading at $27.42, up 3.04% on the day. The price is positioned above its SMA-20 ($26.98), SMA-50 ($26.47), and SMA-200 ($25.22), highlighting ...
What triggered Pfizer shares' latest price surge
Pfizer Inc. (PFE) is trading at $27.15, marking a daily gain of 2.01%. The asset remains above the SMA-20 ($26.98), SMA-50 ($26.47), and SMA-200 ($25.22), indicating strong support across short- ...
Pfizer advances pediatric therapies as Dr Nicole Kulisek drives global treatment expansion
Pfizer is accelerating efforts to expand treatment options for children through the leadership of Dr. Nicole Kulisek in Medical Affairs. Kulisek is spearheading initiatives aimed at developing ...
Pfizer stock forecast for 2030. $10B obesity bet and BRAFTOVI approval bets $45 upside
On February 24, the FDA gave full traditional approval for Pfizer's BRAFTOVI, along with cetuximab and chemotherapy, as a first-line treatment for BRAF V600E-mutant metastatic colorectal ...
Pfizer stock: Mixed technicals and dividend focus drive a sharp downside move
Pfizer Inc. (PFE) is trading at $26.46 after a 3.06% decline for the session. The current price sits below the 20-day Moving Average ($27.10), while remaining above both ...
What is behind Pfizer recent drop in value today
Pfizer Inc. (PFE) is currently trading at $26.56, down 2.67% on the day. The stock sits below its MA-20 ($27.10), but remains above the MA-50 ($26.11) and MA-200 ...
